Ipca Laboratories Limited (NSE: IPCALAB)
India
· Delayed Price · Currency is INR | Market Cap | 399.22B |
| Revenue (ttm) | 85.34B |
| Net Income (ttm) | 6.61B |
| Shares Out | 253.70M |
| EPS (ttm) | 26.05 |
| PE Ratio | 60.39 |
| Forward PE | 39.60 |
| Dividend | 4.00 (0.25%) |
| Ex-Dividend Date | Nov 27, 2024 |
| Volume | 337,655 |
| Open | 1,557.00 |
| Previous Close | 1,566.70 |
| Day's Range | 1,555.85 - 1,606.70 |
| 52-Week Range | 1,041.00 - 1,708.65 |
| Beta | 0.26 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 11, 2024 |
About Ipca Laboratories
Ipca Laboratories Limited, a pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, CIS, and Australasia. It offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. The company also provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabe... [Read more]
Financial Performance
In 2023, Ipca Laboratories's revenue was 77.06 billion, an increase of 23.33% compared to the previous year's 62.48 billion. Earnings were 5.47 billion, an increase of 16.13%.
Financial StatementsNews
Pharma stocks update: IPCA Labs up 3.27%, JB Chem 3.18%, Glenmark 2.90%, Torrent Pharma 2.43%, Divis Labs 2.51%
The pharmaceutical sector showed strong momentum today, with multiple stocks posting notable gains by mid-afternoon. Investors showed increased confidence in pharma companies, driving up their stock p...
Nomura expects IPCA Labs shares to rally over 20% from current price, retains Buy call
Nomura has reiterated its 'Buy' rating on IPCA Laboratories, increasing the target price to Rs 1,750, implying a 20.19% upside in the stock price from its previous close of Rs 1,456